Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Juan Pinelli"'
Autor:
Peter H. O'Donnell, Noah M. Hahn, Elaina M. Gartner, Matthew D. Galsky, Shang Ying Liang, Daniel P. Petrylak, Amal Melhem-Bertrandt, Evan Y. Yu, Juan Pinelli, Arjun Vasant Balar, Elisabeth I. Heath, Bradley Alexander McGregor, Jonathan E. Rosenberg
Publikováno v:
Journal of Clinical Oncology. 37:2592-2600
PURPOSE Locally advanced or metastatic urothelial carcinoma is an incurable disease with limited treatment options, especially for patients who were previously treated with platinum and anti–programmed death 1 or anti–programmed death ligand 1 (P
Autor:
Peter H. O'Donnell, Daniel P. Petrylak, Bradley Alexander McGregor, S.N. Shah, Evan Y. Yu, Zsolt Hepp, Matthew D. Galsky, David I. Quinn, Juan Pinelli, Jonathan E. Rosenberg, Arjun Vasant Balar
Publikováno v:
Annals of Oncology. 30:v367-v368
Autor:
Joseph D. Rosenblatt, Juan Pinelli, Pauline Brice, Keenan Fenton, Timothy M Illidge, Nancy L. Bartlett, Ranjana H. Advani, Joseph M. Connors, Jeffrey Matous, Barbara Pro, Michelle A. Fanale, Radhakrishnan Ramchandren, Andrei R. Shustov, Dana A. Kennedy, Dirk Huebner
Publikováno v:
Blood. 130(25)
This pivotal phase 2 study evaluated the safety and efficacy of brentuximab vedotin in patients with relapsed or refractory (R/R) systemic anaplastic large cell lymphoma (ALCL). After a median observation period of approximately 6 years from first tr
Autor:
Elaina M. Gartner, Evan Y. Yu, Bradley Alexander McGregor, Matthew D. Galsky, Elisabeth I. Heath, Jonathan E. Rosenberg, Noah M. Hahn, Peter H. O'Donnell, Arjun Vasant Balar, Juan Pinelli, Daniel P. Petrylak, Amal Melhem-Bertrandt
Publikováno v:
Journal of Clinical Oncology. 37:4505-4505
4505 Background: Locally advanced or metastatic urothelial cancer (la/mUC) remains a lethal disease with limited treatment options for patients (pts) who progress on or after platinum and/or checkpoint inhibitor (CPI). Enfortumab vedotin (EV) is an a
Autor:
Ramón García-Sanz, Juan Pinelli, Angelo Michele Carella, Amanda F. Cashen, Veronika Bachanova, Jeffrey Matous, Andy I. Chen, Auayporn Nadamanee, Dirk Huebner, Sally Arai, Edward Agura, Emily K. Larsen
Publikováno v:
Biology of Blood and Marrow Transplantation. 23:S46
Autor:
Andrei R. Shustov, Barbara Pro, Jeffrey Matous, Dirk Huebner, Ranjana H. Advani, Juan Pinelli, Joseph M. Connors, Timothy M Illidge, Pauline Brice, Keenan Fenton, Joseph D. Rosenblatt, Nancy L. Bartlett, Michelle A. Fanale, Radhakrishnan Ramchandren
Publikováno v:
Blood. 128:4144-4144
Background Systemic anaplastic large cell lymphoma (ALCL) is a CD30-expressing subtype of peripheral T-cell lymphoma (PTCL). Approximately 40 to 65% of ALCL patients (pts) will develop recurrent disease after frontline treatment, with median overall